Compare FLGT & IGD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FLGT | IGD |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 579.9M | 489.0M |
| IPO Year | 2016 | N/A |
| Metric | FLGT | IGD |
|---|---|---|
| Price | $19.68 | $6.38 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $28.33 | N/A |
| AVG Volume (30 Days) | 241.4K | ★ 311.4K |
| Earning Date | 05-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.15% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $18,730,000.00 | N/A |
| Revenue This Year | $10.09 | N/A |
| Revenue Next Year | $12.18 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.46 | $5.58 |
| 52 Week High | $31.04 | $6.41 |
| Indicator | FLGT | IGD |
|---|---|---|
| Relative Strength Index (RSI) | 49.59 | 61.64 |
| Support Level | $13.91 | $5.64 |
| Resistance Level | $19.93 | N/A |
| Average True Range (ATR) | 0.64 | 0.08 |
| MACD | -0.22 | 0.01 |
| Stochastic Oscillator | 21.76 | 92.65 |
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
Voya Global Equity Dividend and Premium Opportunity Fund are a United States-based diversified, closed-end Fund. The primary objective of the Fund is to seek to provide investors with a high level of income from a portfolio of common stocks with historically attractive dividend yields and premiums from call option writing. The secondary investment objective of the company is capital appreciation. Under normal market conditions, the Fund will invest at least 80% of its managed assets in a portfolio of common stocks of dividend-paying companies located throughout the world.